Tag: pharmaceuticals
-
Trial Begins Testing Sickle Cell Blood Therapy
23 June 2015. A clinical trial began enrolling participants testing a synthesized therapy for sickle cell disease to improve the flow of blood cells blocked by the condition and relieve the intense pain that results. The late-stage trial is being conducted by drug maker Pfizer Inc., with biotechnology company GlycoMimetics Inc. in Gaithersburg, Maryland. Sickle…
-
Allied-Bristol Licenses Chinese Root Extract Technology
22 June 2015. A joint venture of drug maker Bristol-Myers Squibb and science commercialization company Allied Minds is licensing research at Harvard University on the actions of a Chinese root extract with therapeutic potential against fibrosis, inflammation, and autoimmune disorders. Financial aspects of the agreement between Harvard and Allied-Bristol Life Sciences were not disclosed. The…
-
Trial Testing Precision Medicine as Skin Cancer Therapy
18 June 2015. A clinical trial is recruiting participants to test targeted molecular therapies as treatments for advanced cases of skin cancer. The study plans to enroll 96 individuals with melanoma, an advanced and dangerous form of skin cancer, found spreading to other organs in the body and cannot be treated with surgery. Melanoma results…
-
Anti-Infection Compound Devised for Dental, Wound Care
18 June 2015. A new formulation of a common antibacterial agent can protect against infections for weeks or months at a time, according to its developers at University of Bristol in the U.K. The team led by Bristol dental materials scientist Michele Barbour is developing Pertinax, an extended antimicrobial compound, and receiving this year’s £25,000…
-
Drug Makers Start Prostate Cancer Patient Registry
17 June 2015. Two companies that developed a drug to treat prostate cancer, began enrolling individuals into a registry of people with prostate cancer to track their quality of care. Astellas U.S., a division of Astellas Pharma in Tokyo, and Medivation Inc., a biotechnology company in San Francisco, created the registry to better understand treatment…
-
Report Evaluates Industry-Academic Biotech Partner Roles
16 June 2015. A report released today by Biotechnology Industry Organization, or Bio, indicates academic research labs are playing an increasingly key role in research and development of new therapies, but it also highlights areas where partnerships between academia and industry are still evolving. Bio released the report, Advancing Translational Research for Biomedical Innovation: Measuring…
-
Trial Underway Testing Immunotherapy for Gout
10 June 2015. An early-stage clinical trial is recruiting patients to test the safety of a treatment for severe gout that harnesses the immune system, but still avoids unwanted immune responses. The trial is conducted by the biotechnology company Selecta Biosciences at two sites in the U.S.: Altoona, Pennsylvania and Dallas, Texas. Gout is a…
-
Grant Funds Exosome Cancer Research, Optioned to Spin-Off
9 June 2015. A new $1.7 million grant from National Cancer Institute is funding research at University of New Mexico on harnessing exosomes as potential cancer therapies, with a spin-off company already optioning the technology for commercial development. The alliance between the university and spin-off company, Exovita Biosciences, includes an agreement between the university and…
-
Biotech Adds Antibiotic Program, Raises $30 Million
8 June 2015. Spero Therapeutics, a developer of antibiotics, is adding a new class of anti-infection drugs to its pipeline, and raised another $30 million to its first venture funding round. The Cambridge, Massachusetts biotechnology company, a spin-off from Massachusetts General Hospital in Boston, was founded in April 2014 to develop therapies addressing the growing…
-
FDA Approves Pediatric HIV Drug Formulation
5 June 2015. The U.S. Food and Drug Administration approved an application for a current HIV drug formulated to better treat infections in infants and young children, especially in limited resource regions. The formulation is a combination of lopinavir and ritonavir in pellet form designed to mix with food, and manufactured by the generic drug…